Risk Factors for Thrombosis and Bleeding and Their Influence on Therapeutic Decisions in Patients with Essential Thrombocythemia

ABSTRACT

The clinical course of essential thrombocythemia (ET) is variable, ranging from microvascular circulation disturbances to severe thromboembolic or hemorrhagic complications in patients who do not have any symptoms for many years. The identification of patients at risk for major thrombosis who need platelet-lowering therapy is important. During the last two decades, several risk factors for the development of ET-related thrombotic and bleeding complications have been identified. These include platelet counts, previous thrombotic events, older age, cardiovascular risk factors, hereditary thrombophilia, clonality, and the presence of molecular markers such as PRV-1 or the Janus kinase 2 (JAK2) mutation. According to the presence or absence of these risk factors, individual patients with ET are currently stratified as low-, intermediate-, or high-risk patients. The influence of these risk factors on therapeutic decisions in patients with ET is critically reviewed and discussed in detail.

KEYWORDS

Essential thrombocythemia - risk factors - therapy

REFERENCES

• 1 Finazzi G, Harrison C. Essential thrombocythemia.  Semin Hematol. 2005;  42(4) 230-238
• 2 Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.  Blood Rev. 2005;  19(5) 243-252
• 3 Barbui T, Finazzi G. When and how to treat essential thrombocythemia.  N Engl J Med. 2005;  353(1) 85-86
• 4 Pearson T C. The risk of thrombosis in essential thrombocythemia and polycythemia vera.  Semin Oncol. 2002;  29(suppl 10) 16-21
• 5 Michiels J J, Abels J, Steketee J, van Vliet HHDM, Vuzevski V D. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.  Ann Intern Med. 1985;  102 466-471
• 6 Michiels J J. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia.  Clin Appl Thromb Hemost. 1999;  5 30-36
• 7 Van Genderen P, Michiels J J. Hydroxyurea in essential thrombocytosis.  N Engl J Med. 1995;  333 802-803
• 8 Michiels J J, Koudstaal P J, Mulder A H, Van Vliet HHDM. Transient neurologic and ocular manifestations in primary thrombocythemia.  Neurology. 1993;  43 1107-1110
• 9 Lahuerta-Palacios J J, Bornstein R, Fernandez-Debora F J et al.. Controlled and uncontrolled thrombocytosis. Its clinical role in essential thrombocythemia.  Cancer. 1988;  61(6) 1207-1212
• 10 Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.  J Clin Oncol. 1990;  8(3) 556-562
• 11 Cortelazzo S, Finazzi G, Ruggeri M et al.. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.  N Engl J Med. 1995;  332(17) 1132-1136
• 12 Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.  Br J Haematol. 2000;  110(3) 577-583
• 13 Storen E C, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia.  Blood. 2001;  97(4) 863-866
• 14 Lengfelder E, Hochhaus A, Kronawitter U et al.. Should a platelet limit of 600 x 10(9)/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages.  Br J Haematol. 1998;  100(1) 15-23
• 15 Chim C-S, Kwong Y-K, Lie AK-W et al.. Long-term outcome of 231 patients with essential thrombocythemia.  Arch Intern Med. 2005;  165 2651-2658
• 16 Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts.  Am J Hematol. 1997;  56(3) 168-172
• 17 van Genderen P J, Michiels J J. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia.  Presse Med. 1994;  23(2) 73-77
• 18 van Genderen P J, Leenknegt H, Michiels J J, Budde U. Acquired von Willebrand disease in myeloproliferative disorders.  Leuk Lymphoma. 1996;  22(suppl 1) 79-82
• 19 Griesshammer M, Bangerter M, van Vliet HHDM, Michiels J J. Aspirin in essential thrombocythemia: status quo and quo vadis.  Semin Thromb Hemost. 1997;  23 371-377
• 20 Budde U, Schaefer G, Mueller N, Egli H, Ruggeri Z M, Zimmerman T S. Acquired von Willebrand disease in the myeloproliferative syndrome.  Blood. 1984;  64 981-985
• 21 Budde U, Dent J A, Berkovitz S D, Ruggeri Z M, Zimmerman T S. Subunit composition of plasma von Willebrand factor in patients with the myleproloferative syndrome.  Blood. 1986;  68 1213-1217
• 22 Fabris F, Casonato A, DelBen M G, DeMarco L, Girolami A. Abnormalities of von Willebrand factor in myeloproliferative disease: a relationship with bleeding diathesis.  Br J Haematol. 1986;  63 75-83
• 23 Barbui T, Barosi G, Grossi A et al.. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.  Haematologica. 2004;  89(2) 215-232
• 24 Colombi M, Radaelli F, Zocchi L, Maiolo A T. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients.  Cancer. 1991;  67(11) 2926-2930
• 25 Besses C, Cervantes F, Pereira A et al.. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients.  Leukemia. 1999;  13(2) 150-154
• 26 Tefferi A, Fonseca R, Pereira D L, Hoagland H C. A long-term retrospective study of young women with essential thrombocythemia.  Mayo Clin Proc. 2001;  76(1) 22-28
• 27 Ruggeri M, Finazzi G, Tosetto A, Riva S, Rodeghiero F, Barbui T. No treatment for low-risk thrombocythaemia: results from a prospective study.  Br J Haematol. 1998;  103(3) 772-777
• 28 Randi M L, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies.  J Intern Med. 1999;  246(5) 517-518
• 29 Shih L Y, Lin T L, Lai C L et al.. Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia.  Blood. 2002;  100(5) 1596-1601
• 30 Watson K V, Key N. Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factors.  Br J Haematol. 1993;  83(2) 198-203
• 31 Jantunen R, Juvonen E, Ikkala E, Oksanen K, Anttila P, Ruutu T. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.  Ann Hematol. 2001;  80(2) 74-78
• 32 Jensen M K, de Nully Brown P, Thorsen S, Hasselbalch H C. Frequent occurrence of anticardiolipin antibodies, Factor V Leiden mutation, and perturbed endothelial function in chronic myeloproliferative disorders.  Am J Hematol. 2002;  69(3) 185-191
• 33 Fenaux P, Simon M, Caulier M T, Lai J L, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases.  Cancer. 1990;  66(3) 549-556
• 34 Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.  Am J Hematol. 1996;  52(1) 14-20
• 35 Hehlmann R, Jahn M, Baumann B, Kopcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases.  Cancer. 1988;  61(12) 2487-2496
• 36 van Genderen P J, Mulder P G, Waleboer M, van de Moesdijk D, Michiels J J. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin.  Br J Haematol. 1997;  97(1) 179-184
• 37 Ruggeri M, Gisslinger H, Tosetto A et al.. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.  Am J Hematol. 2002;  71(1) 1-6
• 38 Afshar-Kharghan V, Lopez J A, Gray L A et al.. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia.  Blood Coagul Fibrinolysis. 2004;  15(1) 21-24
• 39 Gisslinger H, Mullner M, Pabinger I et al.. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study.  Haematologica. 2005;  90(3) 408-410
• 40 Gisslinger H, Rodeghiero F, Ruggeri M et al.. Homocysteine levels in polycythaemia vera and essential thrombocythaemia.  Br J Haematol. 1999;  105(2) 551-555
• 41 Faurschou M, Nielsen O J, Jensen M K, Hasselbalch H C. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders.  Am J Hematol. 2000;  65(2) 136-140
• 42 Amitrano L, Guardascione M A, Ames P R et al.. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease.  Am J Hematol. 2003;  72(2) 75-81
• 43 Harrison C N, Donohoe S, Carr P, Dave M, Mackie I, Machin S J. Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis.  Thromb Haemost. 2002;  87(5) 802-807
• 44 Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India.  Hepatology. 2001;  34 666-670
• 45 Janssen H L, Meinardi J R, Vleggaar F P et al.. Factor V Leiden mutation, prothrombin gene mutation and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study.  Blood. 2000;  96 2364-2368
• 46 Harrison C N, Gale R E, Machin S J, Linch D C. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications.  Blood. 1999;  93(2) 417-424
• 47 Chiusolo P, La Barbera E O, Laurenti L et al.. Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia.  Exp Hematol. 2001;  29(6) 670-676
• 48 Andreasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia.  Blood. 2003;  101(2) 783
• 49 Kralovics R, Skoda R C. Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders.  Blood Rev. 2005;  19(1) 1-13
• 50 Cazzola M, Skoda R. Gain of function, loss of control-a molecular basis for chronic myeloproliferative disorders.  Haematologica. 2005;  90(7) 871-874
• 51 Goerttler P S, Steimle C, Marz E et al.. The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.  Blood. 2005;  106(8) 2862-2864
• 52 Teofili L, Pierconti F, Di Febo A et al.. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia.  Blood. 2002;  100(2) 714-717
• 53 Klippel S, Strunck E, Temerinac S et al.. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis.  Blood. 2003;  102(10) 3569-3574
• 54 Johansson P, Ricksten A, Wennstrom L, Palmqvist L, Kutti J, Andreasson B. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.  Br J Haematol. 2003;  123(3) 513-516
• 55 Griesshammer M, Klippel S, Strunck E et al.. PRV-1 mRNA expression discriminates two types of essential thrombocythemia.  Ann Hematol. 2004;  83(6) 364-370
• 56 Goerttler P L, Marz E, Jhansson P L et al.. Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by c-Mpl protein expression and PRV-1 mRNA levels.  Haematologica. 2005;  90(6) 851-853
• 57 James C, Ugo V, Le Couedic J P et al.. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.  Nature. 2005;  434(7037) 1144-1148
• 58 Wolanskyj A P, Lasho T L, Schwager S M et al.. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance.  Br J Haematol. 2005;  131(2) 208-213
• 59 Antonioli E, Guglielmelli P, Pancrazzi A et al.. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.  Leukemia. 2005;  19(10) 1847-1849
• 60 Campbell P J, Scott L M, Buck G et al.. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.  Lancet. 2005;  366(9501) 1945-1953
• 61 Elliott M A, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.  Br J Haematol. 2005;  128(3) 275-290
• 62 Michiels J J, Berneman Z, Van Bockstaele D, van der Planken M, De Raeve H, Schroyens W. Clinical and laboratory features, and pathobiology of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications and the molecular etiology of ET and PV.  Semin Thromb Hemost. 2006;  32 174-207
• 63 Griesshammer M, Hochhaus A. Chronische myeloproliferative Erkrankungen. In: Herausgeber M, Classen R, Dierkesmann H et al. für die deutsche Gesellschaft für Innere Medizin. Rationelle Diagnostik und Therapie in der Inneren Medizin - Leitlinien. München, Germany; Verlag Urban und Fischer Vol. 13 2002 Chapter B2